Breaks Categories: News

WednesdaySep 04, 2024 11:40 am

NetworkNewsBreaks – Telomir Pharmaceuticals Inc. (NASDAQ: TELO) Appoints Pharmaceutical Innovation Veteran as Chief Scientific Advisor

Telomir Pharmaceuticals (NASDAQ: TELO), a pre-clinical-stage company seeking to lead developments in longevity science through the treatment of age-related conditions, today announced the appointment of Dr. Itzchak Angel as Chief Scientific Advisor. Dr. Angel’s extensive career in pharmaceutical innovation spans over 40 years, during which he has been instrumental in the research, development, and regulatory approvals of numerous therapies across various therapeutic areas. Dr. Angel will collaborate with Telomir’s senior management to expedite the pre-clinical and clinical path of Telomir-1, the company’s lead product candidate. According to the announcement, Dr. Angel will concentrate his scientific efforts on unveiling and experimentally…

Continue Reading

WednesdaySep 04, 2024 11:03 am

NetworkNewsBreaks – WiSA Technologies, Inc. (NASDAQ: WISA) Executes Definitive Agreement to Create ‘Larger, More Dynamic Entity’ with Broad Reach

WiSA Technologies (NASDAQ: WISA) today announced the execution of a definitive asset purchase agreement to purchase the Datavault(R) intellectual property and information technology assets of privately held Data Vault Holdings Inc. WiSA will pay $210 million as consideration, consisting of 40 million shares of common stock to be issued at $5 per share plus a $10 million 3-year unsecured promissory note. The transaction is expected to close before December 31, 2024, subject to customary conditions and approvals. The purchase will create a publicly traded data technology and licensing company with an extensive patent portfolio serving multiple industries and government entities…

Continue Reading

WednesdaySep 04, 2024 10:38 am

NetworkNewsBreaks – Eloro Resources Ltd. (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM) Provides Update on Its Iska Iska Silver-Tin Polymetallic Project in Southwestern Bolivia

Eloro Resources (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec, today provided an update on its Iska Iska silver-tin polymetallic project in Potosi Department, southern Bolivia. According to the update, an initial program of 5,700m of diamond drilling in 13 holes in the Santa Barbara starter pit area is planned to better define the vertical and lateral extent of high-grade Ag mineralization. This will be followed by an additional 1,400m in two larger PQ holes for further metallurgical testing in Sn mineralization to…

Continue Reading

TuesdaySep 03, 2024 2:48 pm

NetworkNewsBreaks – SuperCom Ltd. (NASDAQ: SPCB) Announces Additional Orders from European Governments Totaling $2.6M

SuperCom (NASDAQ: SPCB), a global provider of secured solutions for the e-government, Internet of Things (“IoT”) and cybersecurity sectors, has received new orders valued at $2.6 million from different governments in Europe; the company anticipates fulfilling the orders in the next three months. The company offers PureSecurity Suite, an end-to-end electronic monitoring solution that features state-of-the-art GPS tracking, communication and monitoring technologies, as well as a secure software platform providing real-time tracking and reporting. “We are delighted to continue strengthening our collaboration with European governments,” said SuperCom president and CEO Ordan Trabelsi in the press release. “These repeat orders underscore our customers' confidence…

Continue Reading

TuesdaySep 03, 2024 2:27 pm

NetworkNewsBreaks – FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) Announces Closing of Private Placement Final Tranche

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a leading green ammonia company, has closed on a nonbrokered private placement. In addition, the company has issued 8,925,055 units at $0.055 per unit, with each unit consisting of one common share of the company and one common share purchase warrant exercisable at a price of $0.07 until Aug. 29, 2029. Gross proceeds from the placement total an estimated $490,878. The offering is the final tranche of the placement announced in May. The announcement noted that no finders’ fees or commissions were paid in connection with completion of the offering, and all securities issued in connection…

Continue Reading

TuesdaySep 03, 2024 2:06 pm

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Latest BioMedWire Podcast Episode

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is spotlighted in the most recent episode of IBN’s BioMedWire Podcast. During the episode, CNS Pharmaceuticals CEO John Climaco talks with podcast host Carmel Fisher to explain what sets CNSP’s Berubicin and new TPI-287 candidate apart from anything else in development for glioblastoma. The BioMedWire Podcast features fast-paced interviews with experts guiding the next wave of pharmaceutical and biotech innovation. “We are an oncology drug-development company,” said CNS Pharmaceuticals CEO John Climaco during the…

Continue Reading

TuesdaySep 03, 2024 12:55 pm

NetworkNewsBreaks – PaxMedica Inc. (PXMD) Announces Immediate Exercise of Warrants to Total Approximately $884K

PaxMedica (OTC: PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, has entered into definitive agreements for the immediate exercise of certain outstanding warrants. The agreements outline the “purchase up to an aggregate of 4,423,080 shares of common stock of the originally issued in November 2023, having an exercise price of 1.30 per share, at a reduced exercise price of $0.20 per share,” the company stated in the press release. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The announcement noted that PaxMedica will also issue new unregistered warrants to purchase…

Continue Reading

TuesdaySep 03, 2024 12:27 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Material Transfer Agreement to Evaluate DehydraTECH(TM) Technology in Pre-Clinical Setting

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has entered into a Materials Transfer Agreement with a pharmaceutical company. Under the terms of the agreement, the pharmaceutical company will evaluate Lexaria’s DehydraTECH(TM) technology in a pre-clinical setting. Lexaria will be responsible for formulating and supplying certain DehydraTECH compositions, with the pharmaceutical company evaluating the pharmacokinetics of these compositions in animal studies. According to the company, Lexaria has awarded the pharmaceutical company a temporary exclusive license option limited to specific DehydraTECH concepts and formulations under examination. The work is expected to be completed within roughly 6 months…

Continue Reading

TuesdaySep 03, 2024 11:51 am

NetworkNewsBreaks – Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF), American West Metals Report Status Update on Drilling, Surveys at Storm Copper Project

Aston Bay (TSX.V: BAY) (OTCQB: ATBHF), a publicly traded mineral exploration company exploring for high-grade copper and gold deposits in Virginia and Nunavut, Canada, has released an update on drilling activities and geophysical surveys being conducted at the Storm Copper Project, located on Somerset Island, Nunavut. Highlights of the report indicate that drilling has surpassed 20,000 meters with 128 Reverse Circulation (“RC”) drill holes and 14 diamond drill holes now completed; the drilling of a moving-loop electromagnetic (“MLEM”) anomaly in an untested area south of the Thunder Prospect at Storm has intersected strong visual copper sulfides; and the drilling is…

Continue Reading

TuesdaySep 03, 2024 11:16 am

NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Management to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company today announced that its management will present at the H.C. Wainwright 26th Annual Global Investment Conference and host 1x1 investor meetings. The virtual presentation is scheduled for September 9, 2024, at 7 a.m. EST. To view the webcast of the presentation, visit https://nnw.fm/4gbJl To view the full press release, visit https://nnw.fm/yW77M About Clene Inc. Clene…

Continue Reading